eligibility_summary
Eligible: consenting R/R CD19+/CD20+ B‑cell malignancies (B‑ALL, CLL/FL/MZL/LPL/HCL, DLBCL/BL/MCL) with measurable/evaluable disease, ECOG 0–2, and expected survival >3 months. Lymphoma needs prior anti‑CD20 plus anthracycline and R/R per protocol, B‑ALL meets R/R or HSCT‑ineligible/relapsed. Exclude: major cardiac disease, active GVHD, severe lung disease, other advanced cancers, uncontrolled infection, autoimmune/immune deficiency, active HBV/HCV, HIV/syphilis, severe biologic allergy, CNS disease, pregnancy/lactation/planned pregnancy, or other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CD19 & CD20 bispecific CAR T cells—autologous, genetically engineered cellular immunotherapy. Mechanism of action: Patient T cells are modified to express a single CAR with tandem scFvs that bind either CD19 or CD20, plus a 4-1BB co-stimulatory and CD3ζ signaling domain. Antigen engagement triggers T-cell activation, expansion, and cytotoxic killing of malignant B cells, dual targeting reduces antigen-loss escape. Targets (cells/pathways): CD19+ and/or CD20+ B-cell malignancies (B-ALL, indolent/aggressive B-cell lymphomas), engages 4-1BB signaling in CAR T cells, eliminates CD19/CD20-expressing B cells. Phase/Design: Phase I/II, single-arm, open-label.